Glucose metabolism disorders in cystic fibrosis (CF-GMD) are common and have a negative clinical impact. Screening currently relies on the oral glucose tolerance test (OGTT); however, this procedure is burdensome and complex for both patients and healthcare providers. Continuous glucose monitoring (CGM) is increasingly used in CF centers for CF-GMD screening, either alone or alongside the OGTT. While long-term (one-year) OGTT reproducibility is known to be poor, the short- and medium-term reproducibility of CGM remains unknown. This examination is poised to become a major tool in CF-GMD investigation, upon which critical therapeutic decisions could be based. The primary objective of this project is to evaluate the short-term variability of CGM data.
Patients aged 10 to 17 years
Diagnosed with cystic fibrosis (CF)
Managed by the pediatric CF care center (CRCM) of the Groupement Hospitalier Est
Patients presenting with one of the following three stages are included: normal glucose tolerance with or without indeterminate glucose tolerance (INDET), impaired fasting glucose (IFG), and impaired glucose tolerance (IGT)
Patients with treated or untreated diabetes
Patients presenting with a pulmonary exacerbation and currently receiving antibiotic therapy
Patients participating in another clinical trial that could interfere, in the investigator's judgment, with the study findings
Refusal of the patient and/or the legal guardian(s) to participate in the study
Single group
Continuous Glucose Monitoring
DeviceUpon enrollment, patients will be equipped with a continuous glucose monitoring (CGM) sensor (Dexcom ONE+). Sensors will be placed on the posterior aspect of the dominant arm at M0, M3, and M6, and additionally on the non-dominant arm at M0 only, in order to evaluate site-dependent variability. At each time point, the sensors will be worn for 7 days to record various CGM parameters, including glycemic variability (analyzed between M0-M3 and M0-M6).
Eating Habits Questionnaire
Other interventionA 7-day dietary diary will be completed at M0, M3, and M6.
Use of an actigraphy watch
Other interventionParticipants will wear an actigraphy watch during 7 days at M0, M3 and M6
The variability of the "time in range" (%) parameter (70-140 mg/dL) between M0 and M3.
The variability of the "time in range" (%) parameter (70-140 mg/dL) between M0 and M3.
The variability of other CGM parameters between M0 and M3: percentage of time in hypoglycemia (<70 mg/dL)
The variability of other CGM parameters between M0 and M3: percentage of time in hypoglycemia (\<70 mg/dL)
The variability of other CGM parameters between M0 and M3: percentage of time in hyperglycemia (>140 mg/dL)
The variability of other CGM parameters between M0 and M3: percentage of time in hyperglycemia (\>140 mg/dL)
The variability of other CGM parameters between M0 and M3: glycemic variability (%)
The variability of other CGM parameters between M0 and M3: glycemic variability (%)
The variability of other CGM parameters between M0 and M3: mean glucose level (mg/dL)
The variability of other CGM parameters between M0 and M3: mean glucose level (mg/dL)
Click on the lead sponsor to view all of their trials.
This trial is not recruiting at the moment. You can still explore other options:
